miR-203 is a predictive biomarker for colorectal cancer and its expression is associated with BIRC5
Tóm tắt
The purpose of this study was to explore the role of miR-203 in colorectal cancer (CRC) and evaluate the correlation between miR-203 and BIRC5. The expressions of miR-203 in the tissues of 122 CRC patients (with non-tumor tissues as controls) and those from 30 healthy donors were detected by TaqMan® MicroRNA assay. BIRC5s expressions in CRC and non-tumor tissues were detected by immunohistochemistry. Significantly less miR-203 was expressed in CRC tissues (P < 0.05) than in non-tumor tissues. Furthermore, low expression level of miR-203 was correlated with distant metastasis (DM), lymph node metastasis (LNM), and TNM stage (P < 0.05), but there were no significant differences between tumor size or gender. The positive expression rates of BIRC5 in CRC and non-tumor tissues were 73.77 % (90/122) and 30.32 % (37/122), respectively. The expression intensity of BIRC5 in CRC was significantly higher than that of non-tumor tissues (P < 0.05). It was significantly correlated with DM, LNM, and TNM stage (P < 0.05). Finally, miR-203 expression was negatively associated with that of BIRC5 (r = −0.8150, P < 0.05). In conclusion, miR-203 was down-regulated in CRC tissues and involved in the onset and progression of CRC. The expressions of miR-203 and BIRC5 in CRC were significantly negatively correlated, suggesting that BIRC5 may be regulated by miR-203. miR-203 is a potential suppressor and predictive biomarker for CRC.
Tài liệu tham khảo
Siegel R, Desantis C, Jemal A. Colorectal cancer statistics. CA Cancer J Clin. 2014;64(2):104–17.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.
Tao K, Yang J, Guo Z, Hu Y, Sheng H, Gao H, Yu H, et al. Prognostic value of miR-221-3p, miR-342-3p and miR-491-5p expression in colon cancer. Am J Transl Res. 2014;6(4):391–401.
AG X, ZJ Y, Jiang B, Wang XY, Zhong XH, Liu JH, Lou QY, Gan AH. Coloerectal cancer in Guangdong Province of China: a demographic and anatomic survey. World J Gastroenterol. 2010;16:906–65.
Weitz J, Koch M, Debus J, Hohler T, Galle PR, et al. Colorectal cancer. Lancet. 2005;365:153–65.
Kozomara A, Griffths-Jones S. miRBase: annotationg high confidence microRNAs using deep sequencing data. Nucleic Acids Res. 2014;42:68–73.
Earle JS, Luthra R, Romans A, et al. Association of microRNA expression with microsatellite instability status in colorectal adeno carcinoma[J. Mol Diagn. 2010;12:433–40.
Chen DL, Wang ZQ, Zl Z. Identificantion of miR 214 as a negative regulator of colorectal cancer liver metastasis via regulation of FGFR 1 expression. Hepatology. 2014;60(2):598–609.
Zhang H, Li W, Nan F, Wang H, Xu Y, et al. MicroRNA expression profile of colon cancer stem-like cells in HT 29 adenocarcinoma cell line. Biochem Biophys Res Commun. 2011;404:273–8.
Iorio MV, Croce CM. MicroRNA dysregulation in cancer: diagnostics, monitoring, and therapeutics. A comprehensive review. EMBO Mol Med. 2012. doi:10.1002/emmm.201100209.
Pavlyukov MS, Antipova NV, Balashova MV, et al. Survivin monomer plays an essential role in apoptosis regulation. J Biol Chem. 2011;286:23296–307.
Lamers F, Schild L, Koser J, et al. Targeted BIRC5 silencing using YM155 causes cell death in neuroblastoma cells with low ABCB1 expression. Eur J Cancer. 2012;5:763–71.
Tao H-Q, He X-J, Ma Y-Y, et al. Evaluation of REG4 for early diagnosis and prognosis of gastric cancer. Hum Pathol. 2011;42:1401–9.
Hussain MU. Micro-RNAs (miRNAs): genomic organization, biogenesis and mode of action. Cell Tissue Res. 2012;349(2):405–13.
Smith CM, Watson DI, Michael MZ, Hussey DJ. MicroRNAs development of Barrett’s esophagus, and progression to esophageal adenocarcinoma. World J of Gastroenterology 2010;6:531–537.
Furuta M, Kozaki K-i, Tanaka S, et al. miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma. Carcinogenesis. 2010;31(5):766–76.
Viticchie G, Lena AM, Latina A, Formosa A, Gregersen LH, et al. miR-203 controls proliferation, migration, and invasive potential of prostate cancer cell lines. Cell Cycle. 2011;10(7):1121–31.
Zhang Z, Zhang B, Li W, Fu L, Fu L, et al. Epigenetic silencing of miR-203 upregulates SNAI2 and contributes to the invasiveness of malignant breast cancer cells. Genes Cancer. 2011;2(8):782–91.
Wang W, Wanjun L, Hui S, Dongyue C, Xinjun Y, Jisheng Z. miR-203 inhibits proliferation of HCC cells by targeting Survivn. Cell Biochem Funct. 2013;31:82–5.
Chiang Y, Song Y, Wang Z, Chen Y, Yue Z, Xu H, Xing C, Liu Z. Aberrant expression of miR-203 and its clinical significance in gastric and colorectal cancers. J Gastrointest Surg. 2011;15(1):63–70.
Zheng Jiang C, Li Hua H, ShaoJun H. Polymorphism of survivin promoter regions—31 g/C and gastric cancer. Cancer. 2008;27(3):258–63.
Ulukus EC, Kargi HA, Sis B, Lebe B, Oztop I, et al. Survivin expression in non-small-cell lung carcinomas: correlation with apoptosis and other apoptosis-related proteins, clinicopathologic prognostic factors and prognosis. Applied Immunohistochemistry &Molecular Morphology. 2007;15:31–7.
Karam JA, Lotan Y, Ashfaq R, Sagalowsky AI, Shariat SF. Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder. Urology. 2007;70:482–6.
Li QX, CongYa Y, XiaoLu Y, et al. FGFR1 and survivin expression analysis of clinical significance in breast infiltrating ductal carcinoma tissue. Chinese Journal of Cancer Prevention and Treatment. 2013;20(17):1315–22.
Yan Z, QiChang Y, HongBing L, et al. The expression of osteopontin, survivin and BCL—2 and clinical significance of cervical lesions. Cancer Research on Prevention and Treatment. 2013;4(1):83–6.
Zhou XL, Lin CC. Survivin and angiotensin-converting enzyme polymorphisms with risk of colorectal cancer; a systematic review and meta-analysis. World J Surg Oncol. 2015;13:27.